In the randomized controlled PARTNER ( Placement of Aortic Transcatheter Valve ) I trial , 657 patients from cohort A ( operable high risk ) were randomly assigned to SAVR or TAVR ( transfemoral [ TF ] if iliofemoral access was suitable or transapical [ TA ] if not ) and received the designated treatment .